期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; ()
Introduction Cyclin-dependent kinase 4/6 inhibitors are new generation drugs that have recently been used in patients with hormone receptor-positive a......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (3)
Background Immune checkpoint inhibitors (ICIs) have changed the landscape of management of advanced cancers. It is imperative to evaluate the safety o......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (3)
Introduction Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform pap......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (8)
Objective Palbociclib, a highly selective reversible CDK4-6 kinase inhibitor, is indicated in combination with an aromatase inhibitor or in combinatio......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (6)
Introduction Despite treatment with antiemetic medications, nausea remains uncontrolled for many children receiving chemotherapy. One reason is that r......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (7)
Purpose Occupational exposure is a long-standing public health concern, which has drawn more and more attention in recent years to the problem of how ......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (7)
Introduction Recent advances in technology have made it possible to develop robots for preparing injectable anticancer drugs. This study aims to compa......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (8)
Introduction Cardiovascular complications can occur in oncology patients secondary to certain cancer therapies. Pharmacists are involved in the care o......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (7)
Introduction Capecitabine is a molecule of choice in the therapeutic arsenal of anticancer drugs used in Morocco for the treatment of breast cancer an......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (6)
Introduction Acute toxic leukoencephalopathy (ATL) is a rare complication of cancer treatment, with symptoms varying from mild cognitive impairment to......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; ()
Background The introduction of CDK 4/6 inhibitors for breast cancer patients has contributed to increased ambulatory patient visits for oncologists. T......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (7)
Introduction Medication reconciliation as part of a Comprehensive Geriatric Assessment by a specialist pharmacist is a process that has been shown to ......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (7)
Introduction Non-small cell lung cancer (NSCLC) is the most common histological subtype of lung cancer. Osimertinib has been recommended as first-line......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (8)
Objective: To provide an integrated approach for deprescribing practice in oncology setting. Data sources: The data on deprescribing in oncology setti......
期刊： JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023; 29 (4)
Introduction The role of a community pharmacist is well recognized in the literature as the most accessible health care provider that promotes health ......
